BioSenic develops innovative treatments for autoimmune diseases, specifically an arsenic trioxide-based treatment and cell therapy products. The company self-describes its offerings as unique.

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.

COM:BIOSENIC

BioSenic

Last Close

0.01

22/11 16:13

Market Cap

3.49M

Beta: -

Volume Today

856.04K

Avg: -

locale

market

industry

website

ipo date

peer of

Metrics